

# Innovation Showcase

## Revolutionising drug-delivery for women

Dr Janet Halliday



Calla Lily  
Clinical Care



CONTROLLED RELEASE SOCIETY  
**CRS 2024** Annual Meeting  
AND Exposition  
JULY 8-12, 2024 • BOLOGNA, ITALY

INTEGRATING  
**Delivery Science**  
ACROSS DISCIPLINES



# The problem

Current methods of drug-delivery for indications in fertility, pregnancy and a range of gynaecological conditions are profoundly inadequate for millions of women around the world.

Vaginal delivery has multiple medical benefits and can avoid the need for painful daily injections – but existing products are flawed and cause stress, uncertainty and inconvenience.



Calla Lily  
Clinical Care



# Our solution: the **Callavid®** device

Patented drug-delivery platform enables clean and hygienic delivery of medicines and hormones, with core underlying tech cleared by US FDA

## Folding mini-liner


sits between labia, absorbs excipients & increased bodily fluid discharge

## Sheath

flexible & breathable, hygienic insertion & removal

## Scaffold

selectively absorbs aqueous bodily fluid discharge, but not the medication



## Drug formulation

joined to tip, or coated onto scaffold (dependent on excipients)

- Leakage protection
- Placement and dosage confidence
- Comfort and convenience
- Mess-free insertion and removal
- Reduced variability in drug absorption




# The market opportunity

\$20bn<sup>+</sup> potential through numerous use cases for our versatile platform

- **Fertility & Pregnancy:** Progesterone for IVF & Miscarriage  
4 million pregnancies and 1 in 4 pregnancies end in miscarriage
- **Vaginal Microbiome:** Multi-strain live biotherapeutic (LBP) delivery for vaginal dysbiosis / Bacterial Vaginosis  
250 million BV cases annually with high recurrence
- **Future Indications / Other drugs inc. Cancer & OTC medications:** e.g. Vaginal Candidiasis, Cervical Cancer, Vulvovaginal Atrophy, Haemorrhoids, etc.
- **Diagnostic Sample Collection:** e.g. Endometriosis detection tests reliant upon unique aspects of our device

# Forecast revenue— drug-delivery platform

Success with progesterone delivery is the springboard for several further applications including vaginal microbiome & oncology



# Our team is passionate about women's health

## LEADERSHIP

**Thang Vo-Ta**  
co-founder & CEO



Ex Goldman Sachs IB/PE, *The Times* Top 100 Entrepreneur, *The Manufacturer* Top 20 Exemplar

**Professor Andrew Lewis** PhD FREng  
principal scientist



50+ patents, Ex Head of R&D / Inventor at Biocompatibles/BTG (acquired by Boston Scientific)

**Lara Zibners** MD MMed MBA FAAP FACEP  
co-founder & director



Pediatric ER doc, author, patient-perspective IVF experience

**Akeel Khan** MBA  
chief product officer



Large-scale automation & complex manufacturing expertise


## ADVISORS

**Dr Stuart Lavery**  
Divisional Clinical Director  
Women's Health / Reproductive Medicine (UCLH), Official Spokesperson British Fertility Society



**Professor Siobhan Quenby**  
Director Biomedical Research Unit in Reproductive Health, Professor of Obstetrics Univ of Warwick

**Dr Kelle Moley**  
VP, Global Translational and Clinical R&D; Head of Reproductive Medicine & Maternal Health – Ferring, former Deputy Director of Reproductive Health at the Bill & Melinda Gates Foundation



**Dr Annalisa Jenkins**  
Prior senior leadership roles at Merck Serono, Bristol Myers-Squibb, and Dimension Therapeutics. Board Director of Oncimmune, AVROBIO, COMPASS Pathways, Affimed and Mereo Biopharma



**Dr Janet Halliday**  
Former Associate VP – Ferring Controlled Therapeutics & External Technology

